Get the latest news, insights, and market updates on STE (STERIS plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
STERIS plc (STE) Remains in Focus as Analysts Reaffirm Confidence
STERIS plc (NYSE:STE) is one of the best medical technology stocks to invest in. On February 5, Citizens reiterated its Market Outperform rating on STERIS plc (NYSE:STE) and kept the $280 price target on the shares. The firm made this move in reaction to STERIS’s Q3 FY2026 financial results. STERIS beat revenue expectations by about […] Feb 15, 2026 - $STE
The 5 Most Interesting Analyst Questions From STERIS’s Q4 Earnings Call
STERIS’s fourth quarter results received a negative reaction from the market despite surpassing Wall Street’s revenue expectations and reporting adjusted earnings per share in line with consensus. Management attributed the quarter’s performance to broad-based volume growth across all segments, with particular strength in healthcare services and consumables. However, CEO Daniel Carestio acknowledged that margin pressures from increased tariffs and inflation more than offset the positive impacts o Feb 11, 2026 - $STE
Stronger Earnings And Dividend Payout Could Be A Game Changer For STERIS (STE)
STERIS plc has reported past third-quarter 2025 results showing sales of US$1,496.2 million and net income of US$192.9 million, with earnings per share rising versus the prior year, and also confirmed a quarterly dividend of US$0.63 per share payable on March 19, 2026. The combination of higher sales and earnings over both the quarter and the first nine months of the fiscal year highlights ongoing operational momentum across STERIS’s business. With this backdrop of improved earnings and a... Feb 9, 2026 - $STE
STERIS Q3 Earnings Call Highlights
STERIS (NYSE:STE) executives highlighted broad-based third-quarter fiscal 2026 growth, improved earnings, and ongoing tariff headwinds during the company’s earnings call, while maintaining full-year guidance and pointing to a more challenging comparison in the fourth quarter. Third-quarter results: Feb 7, 2026 - $STE
STERIS (STE) Q3 2026 Earnings Call Transcript
Karen Burton: And I do have a few words to caution before we open for comments. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS' securities filings. Feb 5, 2026 - $STE
Is It Too Late To Consider STERIS (STE) After A 20% One-Year Share Price Gain?
If you are wondering whether STERIS at around US$261 per share is still a reasonable entry point or starting to look stretched, you are not alone. The stock has seen a 0.5% decline over the last 7 days, a 4.7% return over the past month and year to date, and a 20.5% return over the last year, which naturally raises questions about how much of its story is already reflected in the price. Recent coverage of STERIS has focused on its role in healthcare products and services and how investor... Feb 4, 2026 - $STE
Steris (STE) Meets Q3 Earnings Estimates
Steris (STE) delivered earnings and revenue surprises of -0.10% and +1.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 4, 2026 - $STE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple